The regulatory sequences upstream of E1a, the first viral protein expressed upon infection of cells with adenovirus, have binding sites for multiple transcription factors including two binding sites for E2f and five binding sites for Pea3. We evaluated the impact of deletions, which remove one or more of these transcription factor-binding sites on the expression of E1a in a panel of tumor cells and non-transformed cells. We demonstrated that specific deletions in the E1a enhancer markedly reduced the expression of E1a in growth-arrested cells while having a minimal impact on the expression of E1a in a panel of tumor cells. In particular, deletion of a 50-bp region located from À305 to À255 upstream of the E1a initiation site resulted in marked reduction of E1a and E1b expression and cytolytic activity in growth-arrested cells, while retaining near wild-type of expression of E1a and E1b and cytolytic activity in tumor cells. This deletion removed two Pea3 sites and one E2f site. The characteristics of this vector, TAV-255, was compared with dl1520 (Onyx-015) and demonstrated restricted cytolytic activity in growth-arrested cells similar to dl1520 and superior cytolytic activity in a panel of tumor cell lines. In this current study, we demonstrate that TAV-255, an E1a enhancer deletion vector, possesses tumor selective expression of both E1a and E1b along with potent tumor-selective oncolytic activity.
Introduction
Despite extensive knowledge of the underlying molecular mechanisms that cause cancer, most advanced cancers remain incurable with current chemotherapy and radiation protocols. Oncolytic viruses have emerged as a platform technology that has the potential to significantly augment current standard treatment for a variety of malignancies.
1,2 dl1520 (ONYX-015), which has a deletion of the viral E1b-55k gene, was postulated to confer tumor-selective replication in tumors with defects in the p53 pathway.
3 E1b-55k binds and inactivates p53, permitting unscheduled DNA synthesis and viral replication. Inactivation of p53 by E1b-55k, although critical for efficient replication of adenovirus in normal cells, was hypothesized to be irrelevant in tumors having inactivating mutations in the p53 pathway. Preclinical studies demonstrated that a wide range of human tumor cells with mutant or normal p53 gene sequences supported the replication of dl1520 in cell culture, demonstrating that permissive viral replication in tumors cells was not strictly dependent on the p53-binding effects of E1b-55k. 4, 5 Subsequent analysis demonstrated that E1b-55k is a multifunctional protein that, in addition to binding and inactivating p53 during the early phase of infection, facilitates mRNA transport across the nuclear membrane during later phases of infection. 6, 7 The lack of efficient mRNA transport due to the deletion of E1b-55k resulted in lower viral replication even in tumor cells when compared with wild-type Ad5. Detailed analysis demonstrated that the loss of the mRNA transport function provided by E1b-55k could be complimented in tumor cell lines, suggesting a novel mechanism of tumor-selective viral replication. 8 However, complementation of lost functions due to the deletion of E1b-55k was incomplete in most tumor cells. Consequently, the titer and cytolytic activity of dl1520 in tumor cells was often one to two logs lower than wild-type Ad5 in the same tumor cells. 5 Clinical trials were conducted using dl1520 in a variety of malignancies. These studies included patients with head and neck, colorectal, pancreatic, lung, breast and brain cancer and demonstrated the safety and tolerability of this oncolytic virus when administered alone or with chemotherapy. [9] [10] [11] [12] However, objective clinical responses following dl1520 administration were uncommon raising concerns that this virus, although well tolerated by intratumoral, intravenous and even intraarterial administration, lacked sufficient potency to be broadly applicable as a therapeutic agent. 11 The low viral titer for d11520 in various tumor cell lines, when compared with wild-type Ad5, raised concerns that the potency of d11520 was not sufficient to be clinically active as an anticancer agent. In addition, E1a, the first protein produced by the virus, was not under tumor-selective control, permitting expression of this potent viral protein in normal cells as well as tumor cells. Since the function of E1a is to facilitate entry of cells into cell division, an oncolytic virus would optimally have both E1a and E1b under tumor-selective control. Extensive work has been directed at developing a tumor-selective virus with improved anti-tumor potency when compared with d11520. One approach that we and others have taken for making oncolytic viruses has been to insert tumor-selective promoter elements upstream of critical transcription units including E1a, E1b and E4. [13] [14] [15] [16] [17] [18] Incorporation of heterologous promoter elements, such as the promoter for prostate-specific antigen, carcinogenic-embryonic antigen, E2F1 and telomerase, has achieved variable levels of tumor-selective replication. The potential clinical utility of viruses using heterologous promoters to provide tumor-selective replication has been limited by nonselective and leaky gene expression, diminished capacity of these vectors to replicate when compared with the wild-type virus and recombination events due to the heterologous promoter sequence. 16 Thus, there is a need for improved oncolytic or anti tumor viral activity.
The adenoviral Ela transcriptional control region has multiple regulatory elements including two binding sites for E2F1 and five binding sites for Pea3. 19 These transcription factors are commonly aberrantly expressed in tumor cells. 20, 21 We performed a series of selective deletions of the E1A promoter to determine whether a minimal deletion in the E1A would lead to tumor selectivity and cytotoxicity. We demonstrated that deletion of a 50-nucleotide region between nucleotides À305 and À255, which included two of the five Pea3 and one of the two E2F sites, resulted in a marked reduction of E1a and E1b expression and viral replication in growth-arrested, non-transformed pulmonary cells while retaining near normal E1a and E1b expression and viral replication in tumor cell lines.
Materials and methods

Culturing conditions and cell lines
The HEK-293A (adenovirus E1-transformed human embryonic kidney cells), HeLa (cervical cancer), A549 (lung cancer), LNCaP (prostrate cancer), Calu-6 (lung cancer), PANC-1 (pancreatic cancer), and MRC-5 and IMR-90 (lung fibroblast) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA), and were grown in Dulbecco's-modified Eagle's medium supplemented with 10% fetal calf serum in the presence of 5% CO 2 . Primary cells were contact inhibited by growing them to 100 percent confluency and followed by prolonged (3-4 day) incubation in complete medium.
Reconstruction of mutation into the Ad5 genome Wild-type Ad5 (Dl309), partial deletion of E3 region and various deletion mutants of Ad5 E1A promoter/enhancer, Dl309-6, Dl340-12 and Dl87 were kindly provided by Patrick Hearing (Stony brook University, New York City, NY). To construct TAV-255 virus, the E1a promoter enhancer region was deleted using the adenoviral vector plasmid pXC1 (Microbix Biosystem, Toronto, Ontario, Canada) using QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to its recommended manual. Primer d194_243_F 5 0 -AAAGTGA CGTTTTTGGTGTGCGCCGGTGTTTTGGGCGTAAC CGAGTAAGATTTGGCCA-3 0 and d194_243_R 5 0 -TG GCCAAATCTTACTCGGTTACGCCCAAAACACCG GCGCACACCAAAAACGTCACTTT-3 0 were used for this deletion. The obtained plasmids named pXC1_TAV-255 were amplified in E-coli, sequenced, and purified using HiPur Plasmid Filter Midiprep Kit (Invitrogen, Carlsbad, CA). To obtain adenovirus TAV-255, pXC1_ TAV plasmids were co-transfected with pJM17 into HEK-293 cells (ATCC) using the Fugene6 Transfection Reagent (Roche, Basel, Switzerland). Cells were overlaid with 1.0% Sea Plaque Agarose in culture medium to obtain single plagues in 12 days. After two rounds of plague purification, viruses from a single plaque were amplified in HEK-293 cells. Viral DNA was extracted from culture supernatant using AccuPrep Genomic DNA Extraction Kit (Bioneer, Alameda, CA) and sequenced to confirm expected mutations.
Virus infection and quantification
All the viruses were multiplied in HEK-293A cells. Cells were infected with multiplicity of infection (MOI) of 5 and after 3 days post infection, cells were collected and re-suspended in complete medium and lysed by three cycles of freeze thaw. Lysates were clarified by passing through 0.4 mm filter (Millipore, Billerica, MA). Glycerol was added to the samples to a final concentration of 10 % (v/v) and freezed to À80 1C. To quantify the virus titer, plaque assay were performed as described by Clontech (Mountain View, CA).
Crystal violet assay
Cells were grown in 24-well plates and infected with various viruses as well as different MOI ranging from 1 to 10. After 3 to 7 days post infection the media was removed and cells were washed with phosphate-buffered saline. Cells were then stained with 1% crystal violet for 15 min at room temperature, followed by rinsing with phosphate-buffered saline.
Preparation of cell lysate and immunoblot analysis
For the western blot analysis, cell extracts from various cell lines were prepared by infecting cells with adenoviruses with MOI of 5 and whole cell lysate was prepared using M-PER mammalian protein extraction reagent (Pierce, Rockford, IL) at various hours post infection. Protein was estimated using the Bradford reagent (BioRad, Hercules, CA) and 25 mg of protein samples were boiled following the standard protocol for 5 min in sample buffer containing 2% SDS, 100 mM dithiothreitol, 0.05 M Tris-HCl (pH 6.8), 10% glycerol and 0.1% bromophenol blue. Proteins were analyzed on 4 to 12% bis-Tris gels according to the manufacturer's instructions (Invitrogen). The proteins were separated by SDS-polyacrylamide gel electrophoresis and run on a 4-12% bis-Tris gel and transferred onto a polyvinylidene difluoride membrane, Immobilon-P sq (Millipore) as described by manufacturer.
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The E1a and E1b proteins were detected using a polyclonal antibody against Ad2 E1A protein (Santa Cruz, Santa Cruz, CA) and monoclonal antisera against E1b-55k protein, received from Dr AJ Levine (New Jersey).
Real time quantitative-PCR analysis RNA was extracted using the RNase Easy plus mini kit (Qiagen, Valencia, CA) and 5 mg of total RNA was reverse transcribed into cDNA using AMV Reverse Transcriptase (Invitrogen). Quantitative PCR was performed in triplicate using Power Cyber green reagent from Applied Biosystem (Carlsbad, CA) and reaction was performed on an AB Prism 7900 HT sequence detection system. RNA samples without reverse transcriptions were used as a control. Data were analyzed using SDS 2.2.1 software provided by the Applied Biosystems.
Plasmid construction
Adenovirus (Ad5) E1A promoter/enhancer DNA sequence ( þ 52 to À357) was PCR amplified using the primers Ad143F and Ad552R (forward 5 0 -GGGGTACCACATG TAAGCGACGGATGTGGC3 0 and reverse 5 0 -AAACTCG AGCCCGGTGTCGGAGCGGCT-3 0 ) having 5 0 BamHI and XhoI restriction sites, respectively. and inserted into luciferase reporter vector pGL3-Basic, a promoterless and enhancerless vector (Promega, Madison, WI) and named as pE1AP/EGL3. Plasmid was sequenced (Eton biosciences, San Diego, CA) to verify the E1A promoter/enhancer accuracy.
Results
Deletion mutants of E1A transcription control region and analysis of E1A expression in tumor and non-transformed cells In order to design a tumor-specific oncolytic virus based on minimal modification to the viral genome we deleted different short sequences in the E1A promoter. Figure 1 shows a map of the region upstream of the E1a start site.
The E2f and Pea3 transcription factor binding sites and the deletion mutants are shown. To determine if there were differences between the transcriptional control of E1a between tumor and non-transformed cells, we evaluated E1a expression in tumor and non-transformed, growth-arrested cells, infected with the adenoviral constructs as shown in Figure 2 , none of the deletions had a significant impact on E1a expression in A549-transformed cells. However, deletion mutant viruses, dl309-6 and TAV-255, resulted in significant reductions in E1a expression in MRC-5 growth arrested non-transformed cells. Interestingly dl309-6 is outside the previously defined promoter region of E1a. Notably, TAV-255, has a deletion spanning the region from -305 to -255, resulted in almost complete loss of E1a expression from MRC-5 cells but had no measurable impact on E1a expression from A549 cells. To further evaluate this effect, we compared the expression of Comparison of dl1520 (ONYX-015) and TAV-255 on expression of E1a and E1b dl1520 had a deletion of the E1b-55k viral gene but had no modification to restrict E1a expression in nontransformed cells. We evaluated the expression of E1a following infection of A549 and Panc-1 cells with Ad5, TAV-255 and dl1520. The results shown in Figure 5a , demonstrated comparable levels of E1a expression in A549 and Panc-1 cells infected with Ad5, dl1520 and TAV-255. We then evaluated the expression of E1b-55k following infection of MRC-5 and A549 cells with Ad5, dl1520 and TAV-255. As expected, no expression of E1b-55k protein was observed in either cell lines following infection with the E1b-55k deletion vector, dl1520 (Figure 5b ). However, in the A549 cells expression of E1b-55k was equivalent when infected with the wtAd5 or the TAV-255, this in contrast to the diminished expression of E1b-55k when growth-arrested MRC-5 cells were infected with TAV-255. These results indicated functional attenuation of E1b expression in non-transformed cells whereas expression of E1b is retained at Bwild-type levels in tumor cells.
Effect of TAV-255 on cell viability
To determine whether this increase in E1A amounts had an impact on the anti-tumoral activity, cytotoxicity assays were performed. We evaluated the cytolytic activity of TAV-255 in MRC-5, Panc1 and A549 cells. The photomicrographs of cells five days following infection are shown in Figure 6a . These results demonstrated effective lytic activity of TAV-255 in Panc1 and A549 cells, similar to the lytic activity noted with Ad5. In contrast, minimal cytotoxicity was noted with TAV-255 in growth-arrested MRC-5 cells following infection with TAV-255 while extensive cytolytic activity was observed with Ad5 in these cells. These results further confirmed that TAV-255 retains cytolytic activity in these tumor cell lines, while containing minimal cytolytic activity in the non-transformed MRC-5 cells. We then compared the cytolytic activity of TAV-255 with dl1520 in A549 cells. These results are shown in Figure 6b . A549 cells were infected with various levels of input virus ranging from a MOI of 10 to 0.1. The viability of these cells was determined by In contrast, similar cytolytic activity was not observed with dl1520 until an MOI of 3 was achieved. These results confirm that TAV-255 had minimal cytotoxcity in growth-arrested cells, but demonstrated more potent cytolytic activity in A549 cells than achieved with dl1520.
Discussion
The d11520, a prototype of an oncolytic virus, has undergone clinical testing in a variety of malignancies including head and neck, lung, colorectal, ovarian, pancreatic and brain cancers. Over 1000 intra-tumoral injections of d11520 were administered to patients with head and neck tumors and over 200 infusions were administered into the hepatic artery of patients with metastatic colorectal cancer without serious treatmentrelated adverse events. 12, [22] [23] [24] [25] [26] The primary side-effects were grade I/II flu-like symptoms including fevers and chills. While well tolerated, objective response rates to d11520 were restricted to a minority of patients. As the objective response rates to d11520 were modest, efforts have been directed at developing an oncolytic vector with improved potency. Various approaches have been used to improve the tumor-selectivity and potency of oncolytic viruses, including efforts to place E1a and E1b under the control of distinct tumor-specific heterologous promoters. 13, 14, 16, 17 However, these vectors have suffered from leaky transcription of E1a and E1b and decreased viral replication and cytolytic activity compared with wild-type Ad5.
To overcome some of the limitations inherent in the use of heterologous promoters to control the expression of E1a and E1b, we focused our attention on analysis of the endogenous adenoviral promoter and enhancer for E1a. We studied the expression of E1a from viruses with various deletions in DNA sequence upstream of the E1a start site. Enhancer sequences that potentiate transcription independent of position or orientation have been described in a variety of systems including adenovirus. 27 Core sequences were identified 200 to 300 nucleotides upstream of the E1a start site that could potentiate the expression of E1a independent of position or orientation. 27 Previous studies have demonstrated that deletions of this core enhancer sequence resulted in a 2-5 fold decrease in mRNA expression in HeLa cells 5 h post infection. Nevertheless, these deletions had little impact on mRNA expression by 24 h post infection and had no impact on viral replication. 27 However, the previous analysis of the E1a enhancer was performed in tumor cells, primarily HeLa cells, rather than in non-cycling pulmonary cells, the natural host cells for adenoviral type 5 infections. We have extended the analysis of the enhancer region of adenovirus by comparing the impact of deletions within the region upstream of the E1a start site on the expression of E1a in tumor cells and in growtharrested, pulmonary cells. Consistent with the previous publications, we found that deletions within the E1a enhancer region had little impact on E1a expression and viral replication in tumor cell lines. 27 However, we have now demonstrated that various deletions, including deletions outside the previously defined enhancer region, have a significant impact on E1a expression and viral replication in growth-arrested cells. In particular, we found that deletion of a 50-bp sequence of the native Ad5 enhancer that removes one E2F1 site and two Pea3 sites resulted in marked suppression of E1a and E1b mRNA and protein expression in respiratory cells; however, this deletion had little impact on the expression of E1a in a panel of tumor cell lines. We further demonstrated that deletion of a 99-nucleotide sequence upstream of the proposed E1a enhancer substantially reduced the expression of E1a in growth-arrested pulmonary cells while having a minimal impact on the expression of E1a from the tumor cell lines tested. This region encompasses the two Pea3 sites furthest upstream of the E1a start site. In contrast, a small deletion that removed the Pea-3 site Transcriptional-regulated oncolytic virus F Hedjran et al most proximal to the E1a start site had no significant impact on E1a expression in the tumor cells or in the respiratory cells. Furthermore, a 101-nucleotide deletion from the region between the enhancer and the E1a start-site resulted in a 22 to 30% increase in E1a expression in growth-arrested cells without significantly impacting E1a expression from tumor cells. These results demonstrated that deletions involving the enhancer region have profound effects on E1a expression in non-transformed, growth-arrested cells that are not observed in tumor cells. Thus, the adenoviral E1a enhancer region appears more complex and spans a larger region when analyzed in non-transformed cells instead of tumor cells.
The 50 nucleotide deletion of the spanning the region from À255 to À305 encompasses two binding sites for Pea3 and one binding site for E2F1. 19 These transcriptions factors are commonly overexpressed in a wide variety of tumors. E2F is a sequence-specific transcription factor that forms a complex with Rb and has critical roles in regulating cell cycle progression and cellular differentiation. Phosphorylation of Rb by cyclin-dependent kinases results in release of E2F1 and transcriptional activation of genes involved in DNA replication, repair and recombination. 28, 29 Deregulation of the Rb pathway occurs commonly in malignancies and approaches 100% in various tumors including lung cancer. 21 Two binding sites for E2F1 occur in the control region for E1a. The deletion encompassing the two Pea3 sites furthest from the E1a start site had only a moderate impact on E1a expression. However, deletion of the distal E2F site along with the two Pea3 sites immediately flanking the E2F1 site results in significant reduction in expression of E1a, E1b and viral replication in the growth-arrested MRC-5 cells. These results suggested that the E2F1 and/or the Pea3 sites located within this 50 bp fragment were the dominant sites for E1a control in these non-transformed, growtharrested cells or that additional factors impacted by this deletion determine E1a expression.
Pea3 is a member of the highly conserved Ets transcription factor family. Pea3 is normally expressed during embryogenesis and is involved in tissue remodeling events, cell differentiation and proliferation. Pea3 transcriptionally activates a variety of genes including matrix metalloproteases, which function to degrade the extracellular matrix during normal remodeling events. Pea3 is commonly overexpressed in a variety of cancers including breast, lung, colon, ovarian and liver cancer. Overexpression of matrix metalloproteasess is thought to promote metastasis. 20, [30] [31] [32] Previous studies have demonstrated that cooperative binding between the Pea3 sites increases E1a expression. 19 Consequently, the impact of specific transcription factor-binding sites and cooperative binding may be more evident in non-transformed cells where the transcription factors are limiting than in tumor cells where abundant expression of transcription factors may override the need for cooperative binding to enhance transcription of E1a. The relative importance of the various transcription factor-binding sites, alone and as a complex, is under further investigation.
Our results further demonstrate that tumor-selective expression of the E1b transcription unit can be achieved by modification of the E1a enhancer. The E1b promoter is a relatively simple promoter comprised of at TATA box and a GC box, which binds the sequence-specific transcription factor SP-1. Both domains are necessary for efficient expression of E1b. 33 Previous studies have demonstrated that E1b is expressed as a read-through transcript from E1a. 34 Termination of read-through transcription of E1b from E1a by insertion of the betaglobin termination sequence resulted in markedly diminished expression of E1b 35, 36 whereas insertion of a strong promoter such as the CMV promoter obviates the need for read-through transcription. Our findings demonstrated that expression of E1b could be coordinately attenuated with E1a due to the small deletion in the E1a enhancer in growth-arrested cells. These results are consistent with inefficient read-through transcription of E1b in non-transformed cells. In contrast, both E1a and E1b are expressed at near wild-type levels in A549 cells, indicating efficient read-through transcription from E1a in the tumor cells.
E1b 55k is a multifunctional protein critical for viral replication and deletion of this gene results in diminished transport of viral mRNA across the nuclear membrane thereby attenuating the replication of viruses. Consequently, tumor-selective attenuation of the expression of this protein rather than deletion of this gene may improve the potency of this virus in tumor cells while retaining a high-degree of attenuation in non-transformed cells due to decreased expression of both E1a and E1b. We compared the oncolytic activity of TAV-255 to dl1520 in tumor and normal cells and found that TAV-255 was more potent in inducing cell lysis in A549 tumor cells than dl1520 while retaining a similar level of attenuation as dl1520 in non-transformed cells. Therefore, tumor-selective attenuation of critical viral genes, E1a and E1b, by deletion of critical transcription factor-binding sites in the E1a promoter can result in attenuated lytic activity in non-transformed, growth-arrested cells while retaining efficient expression of both E1a and E1b-55k and lytic activity in tumor cells.
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